Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06809764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06809764 · ClinicalTrials.gov record · last posted 2026-08-18

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Name: Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) — clinical trial record (NCT06809764)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: RERUN

StatusRecruiting

PhaseNot specified

SponsorDaiichi Sankyo

Started2025-02-21

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.

Protocol amendment history 1 change detected by DataLookout

2026-08-19

Trial sites expanded: 23 → 36 locations

Trial Details

NCT Number	NCT06809764
Lead Sponsor	Daiichi Sankyo
Conditions	Non-small Cell Lung Cancer
Enrollment	150 participants
Start Date	2025-02-21
Primary Completion	2027-02-12 (estimated)
Study Completion	2027-02-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-18